These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11094856)

  • 41. Pharmacokinetics and pharmacodynamics of two oral forms of cefuroxime axetil.
    Garraffo R; Drugeon HB; Chiche D
    Fundam Clin Pharmacol; 1997; 11(1):90-5. PubMed ID: 9182082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and bactericidal activity of cefuroxime axetil.
    Ginsburg CM; McCracken GH; Petruska M; Olson K
    Antimicrob Agents Chemother; 1985 Oct; 28(4):504-7. PubMed ID: 3878129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ciprofloxacin versus cefuroxime axetil in the treatment of adult patients with acute bacterial sinusitis.
    Klein GL; Whalen E; Echols RM; Heyd A
    J Otolaryngol; 1998 Feb; 27(1):10-6. PubMed ID: 9511113
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ciprofloxacin versus cefuroxime axetil in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group.
    Johnson PA; Rodriguez HP; Wazen JJ; Huck W; Shan M; Tosiello R; Heyd A; Echols RM
    J Otolaryngol; 1999 Feb; 28(1):3-12. PubMed ID: 10077777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime.
    Ruiz-Carretero P; Merino-Sanjuán M; Nácher A; Casabó VG
    Eur J Pharm Sci; 2004 Feb; 21(2-3):217-23. PubMed ID: 14757493
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Killing kinetics of cefuroxime axetil against Haemophilus influenzae in an in-vitro model simulating serum concentration profiles after oral administration.
    Bingen E; Lambert-Zechovsky N; Doit C; Duvignaud P; Georges D; Mariani-Kurkdjian P
    J Antimicrob Chemother; 1991 Oct; 28(4):533-6. PubMed ID: 1761448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative trial of cefuroxime axetil in recurrent urinary tract infections illustrating importance of 6-week follow-up.
    Brumfitt W; Hamilton-Miller JM; Smith GW
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1442-3. PubMed ID: 3674851
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Role of cefuroxime-axetil in the treatment of respiratory tract infections. Bacteriological and pharmacological data].
    Bergogne-Berezin E; Vallée E; Muller-Serieys C
    Therapie; 1991; 46(4):333-7. PubMed ID: 1948811
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Esters of cephalosporins. Part II. Differences in the properties of various forms of the 1-acetoxyethyl ester of cefuroxime.
    Oszczapowicz I; Małafiej E; Szelachowska M; Horoszewicz-Małafiej A; Kuklewicz C; Sierańska E; Denys A; Niedworok J
    Acta Pol Pharm; 1995; 52(5):397-401. PubMed ID: 8960273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of the efficacy and safety of cefuroxime axetil and augmentin in the treatment of upper respiratory tract infections.
    Hebblethwaite EM; Brown GW; Cox DM
    Drugs Exp Clin Res; 1987; 13(2):91-4. PubMed ID: 3582135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of cefuroxime axetil suspension in infants and children.
    Powell DA; James NC; Ossi MJ; Nahata MC; Donn KH
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2042-5. PubMed ID: 1759825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans.
    Arnez M; Radsel-Medvescek A; Pleterski-Rigler D; Ruzić-Sabljić E; Strle F
    Wien Klin Wochenschr; 1999 Dec; 111(22-23):916-22. PubMed ID: 10666802
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and intramuscular bioavailability of cefuroxime sodium in goats.
    ABO EL-SOOUD K; El-Banna HA; Hanafy MS; Goudah A
    Res Vet Sci; 2000 Dec; 69(3):219-24. PubMed ID: 11124092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cefuroxime axetil in the treatment of Salmonella typhi infection (enteric fever) in adults.
    Deshpande AK; Joshi SR; Lal HM; Cooverji ND; Ajay S
    J Assoc Physicians India; 1996 Nov; 44(11):786-9. PubMed ID: 9251454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of dose doubling with probenecid for sustaining serum cefuroxime levels.
    Garton AM; Rennie RP; Gilpin J; Marrelli M; Shafran SD
    J Antimicrob Chemother; 1997 Dec; 40(6):903-6. PubMed ID: 9462447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
    Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Model simulation of a single oral dose of cefuroxime axetil and the related in-vitro kill kinetics against four bacterial species.
    Silley P; Monsey D; Harris AM
    J Antimicrob Chemother; 1990 Jan; 25(1):83-90. PubMed ID: 2180892
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of cefuroxime axetil on the faecal flora of healthy volunteers.
    Leigh DA; Walsh B; Leung A; Tait S; Peatey K; Hancock P
    J Antimicrob Chemother; 1990 Aug; 26(2):261-8. PubMed ID: 2211457
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relationship of diastereomer hydrolysis kinetics to shelf-life predictions for cefuroxime axetil.
    Nguyen NA
    Pharm Res; 1991 Jul; 8(7):893-8. PubMed ID: 1924141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The stability of Cefuroxime axetil in tablets.
    Jelińska A; Dudzińska I; Zajac M; Oszczapowicz I; Krzewski W
    Acta Pol Pharm; 2005; 62(3):183-7. PubMed ID: 16193810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.